Bioinformatics analysis and experimental validation reveal that CDC20 overexpression promotes bladder cancer progression and potential underlying mechanisms
Authors:
- 4 March 2024
- journal article
- research article
- Published by Springer Nature in Genes & Genomics
- Vol. 46 (4) , 437-449
Abstract
Background Bladder cancer is a prevalent malignancy. CDC20, a pivotal cell cycle regulator gene, plays a significant role in tumour cell proliferation, but its role in bladder cancer remains unclear. Objective This study aimed to analyse CDC20 expression in bladder cancer and explore its roles in tumour progression, treatment response, patient prognosis, and cellular proliferation mechanisms. Methods We systematically analysed CDC20 expression in bladder cancer using bioinformatics. Our study investigated the impact of CDC20 on chemotherapy and radiotherapy sensitivity, patient prognosis, and changes in CDC20 methylation levels. We also explored the role and potential underlying mechanisms of CDC20 in bladder cancer cell growth. We used lentiviral transfection to downregulate CDC20 expression in 5637 and T24 cells, followed by CCK-8, colony formation, scratch, invasion, apoptosis, and cell cycle analyses. Results CDC20 is highly expressed in bladder cancer and is significantly correlated with poor prognosis. Moreover, CDC20 demonstrated high diagnostic potential for bladder cancer (AUC > 0.9). The tumour methylation levels of CDC20 in tumour tissues markedly decreased compared with those in normal tissues, and lower methylation levels were associated with a worse prognosis. Elevated CDC20 expression is linked to increased mutation burden. Our findings suggested a potential association between high CDC20 expression and resistance to chemotherapy and radiotherapy, as CDC20 expression may impact immune cell infiltration levels. Mechanistic analysis revealed the influence of CDC20 on bladder cancer cell proliferation through cell cycle-related pathways. According to the cell experiments, CDC20 downregulation significantly impedes bladder cancer cell proliferation and invasion, leading to G1 phase arrest. Conclusion Aberrantly high CDC20 expression promotes tumour progression in bladder cancer, resulting in a poor prognosis, and may also constitute a promising therapeutic target.Keywords
Funding Information
- the Hunan Provincial Natural Science Foundation of China (2021JJ40427)
This publication has 31 references indexed in Scilit:
- Pelvic Organ Preservation in Non–muscle-invasive Bladder Cancer: Less Is MoreEuropean Urology Focus, 2023
- Knockdown of kinesin family member 4A inhibits cell proliferation, migration, and invasion while promoting apoptosis of urothelial bladder carcinoma cellsCancer Medicine, 2023
- Current Status of Perioperative Therapy in Muscle-Invasive Bladder Cancer and Future DirectionsCurrent Oncology Reports, 2023
- Protodioscin inhibits bladder cancer cell migration and growth, and promotes apoptosis through activating JNK and p38 signaling pathwaysBiomedicine & Pharmacotherapy, 2022
- Targeting Cdc20 for cancer therapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2022
- Cdc20 induces the radioresistance of bladder cancer cells by targeting FoxO1 degradationCancer Letters, 2021
- APCCDC20-mediated degradation of PHD3 stabilizes HIF-1a and promotes tumorigenesis in hepatocellular carcinomaCancer Letters, 2021
- Cell division cycle 20 (CDC20) drives prostate cancer progression via stabilization of β-catenin in cancer stem-like cellsEBioMedicine, 2019
- Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancerWorld Journal of Urology, 2018
- High expression of spindle assembly checkpoint proteins CDC20 and MAD2 is associated with poor prognosis in urothelial bladder cancerVirchows Archiv, 2013